Cita APA

Aparicio, J., Virgili Manrique, A. C., Muñoz Boza, F., Galván, P., Richart, P., Hernando Cubero, J., & Capdevila Castillon, J. (2022). Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: The BEYOND study (GEMCAD 17-01).

Citación estilo Chicago

Aparicio, Jorge, Anna Cristina Virgili Manrique, Félix Muñoz Boza, Patricia Galván, Paula Richart, Jorge Hernando Cubero, y Jaume Capdevila Castillon. Randomized Phase II Trial of FOLFIRI-panitumumab Compared With FOLFIRI Alone in Patients With RAS Wild-type Circulating Tumor DNA Metastatic Colorectal Cancer Beyond Progression to First-line FOLFOX-panitumumab: The BEYOND Study (GEMCAD 17-01). 2022.

Cita MLA

Aparicio, Jorge, et al. Randomized Phase II Trial of FOLFIRI-panitumumab Compared With FOLFIRI Alone in Patients With RAS Wild-type Circulating Tumor DNA Metastatic Colorectal Cancer Beyond Progression to First-line FOLFOX-panitumumab: The BEYOND Study (GEMCAD 17-01). 2022.